INTRODUCTION: Neurodegenerative @entity191 have significant clinical and pathological overlap, making early diagnosis difficult. Cerebrospinal fluid (CSF) biomarkers may aid the differentiation of these disorders, but other than a-synuclein and neurofilament light chain protein, which have limited diagnostic power, specific protein biomarkers remain elusive. OBJECTIVES: To study disease mechanisms and identify possible CSF diagnostic biomarkers through discovery proteomics, which discriminate @entity191 from healthy controls. METHODS: CSF was collected consecutively from 134 @entity1 ; @entity191 (n  =  26), atypical @entity191 (n  =  78, including @entity7463 (n  =  36), multiple system @entity194 (n  =  28), corticobasal syndrome (n  =  14)), and elderly healthy controls (n  =  30). @entity1 were divided into a discovery and a validation set for analysis. The samples were subjected to tryptic digestion, followed by liquid chromatography-mass spectrometry analysis for identification and relative quantification by isobaric labelling. Candidate protein biomarkers were identified based on the relative abundances of the identified tryptic peptides. Their predictive performance was evaluated by analysis of the validation set. RESULTS: 79 tryptic peptides, derived from 26 proteins were found to differ significantly between atypical @entity304 @entity1 and controls. They included acute phase/inflammatory markers and neuronal/synaptic markers, which were respectively increased or decreased in atypical @entity304 , while their levels in @entity1726 subjects were intermediate between controls and atypical @entity304 . CONCLUSION: Using an unbiased proteomic approach, proteins were identified that were able to differentiate atypical @entity191 @entity1 from healthy controls. Our study indicates that markers that may reflect neuronal function and/or plasticity, such as the amyloid precursor protein, and inflammatory markers may hold future promise as candidate biomarkers in @entity304 .

Identification of candidate cerebrospinal fluid biomarkers in XXXX using quantitative proteomics.

@entity1 :: ('9606', 'Species') :: ['participants', 'patients', 'Participants'] @entity304 :: ('MESH:D010302', 'Disease') :: ['parkinsonism'] @entity191 :: ('MESH:D010300', 'Disease') :: ['parkinsonian syndromes', "Parkinson's disease", 'parkinsonian syndrome'] @entity1726 :: ('OMIM:168600', 'Disease') :: ['PD'] @entity194 :: ('MESH:D001284', 'Disease') :: ['atrophy'] @entity7463 :: ('MESH:D013494', 'Disease') :: ['progressive supranuclear palsy']
@entity304 :: (MESH:D010302,Disease) :: ['parkinsonism']
